Scale Up

Denali Therapeutics and Takeda to Jointly Develop and Commercialize Investigational Treatment for FTD-GRN

November 23, 2021

Takeda has exercised an option to co-develop and co-commercialize an investigational, brain-penetrant progranulin replacement therapy for the potential treatment of frontotemporal dementia-granulin.

Computational Fluid Dynamics in Upstream Biopharma Manufacturing Processes

November 03, 2021

Advances in simulation and the development of digital twins.

Corning’s New Cell and Gene Therapy Platform Demonstrates Large-Scale Bioproduction

August 19, 2021

Corning’s new Ascent fixed bed reactor (FBR) system is an automated bioproduction platform designed to significantly improve yields and reduce bioproduction costs.

AGC Biologics Acquires Cell and Gene Therapy Commercial Manufacturing Facility

August 09, 2021

AGC Biologics has acquired Novartis’ Longmont, Colorado, manufacturing facility for the commercial production of cell and gene therapies.

Cellares and Poseida Therapeutics Partner to Accelerate Cell Therapy Manufacturing

July 21, 2021

Cellares has entered into a strategic relationship with Poseida Therapeutics to advance a closed, automated, and scalable cell therapy manufacturing system.

Sparx Therapeutics to Build Commercial Antibody Manufacturing Facility in China

July 09, 2021

Sparx Therapeutics will build its first commercial manufacturing facility in Yangzhou, China, for antibody drug production.

VIVEbiotech Launches Lentiviral Vector Manufacturing Plant for Cell and Gene Therapies

June 08, 2021

VIVEbiotech has opened its new lentiviral vector manufacturing facilities in Spain, expanding capacity for lentiviral vectors for use in cell and gene therapies.

New Biotherapies Push Technological Innovation Forward

June 03, 2021

The emergence of new biotherapeutics is both the driver and result of innovative drug development technologies.

Mitigating Risk in Scale-Up

March 18, 2021

The Testa Center in Sweden provides access to equipment and expertise to help bridge the gap between biopharmaceutical discovery and industrialization.

rBIO Hits Key Lab Milestone with Synthetic Production of Insulin

January 04, 2021

Using rDNA technology to synthesize production of proteins and peptide hormones, the biotech startup has achieved synthetic production of insulin, potentially lowering insulin cost by 30%.